Table 2.
Overall Positive Clinical Sensitivities and Clinical Specificities of Sample Sites for SARS-CoV-2
| Sample Sitea | Clinical Sensitivity, % (95% CI) | Clinical Specificity, % (95% CI) |
|---|---|---|
| Single site | ||
| Unilateral nasopharyngeal | 84.9 (74.2–91.9) | 100 (86.7–100) |
| Unilateral nasal midturbinate | 61.6 (49.4–72.6) | 100 (86.7–100) |
| Throat | 79.5 (68.1–87.7) | 100 (86.7–100) |
| Saliva (n = 104) | 37.5 (26.6–49.7) | 100 (86.7–100) |
| Saliva (N and ORF1ab assay; n = 98)b | 51.5 (39.0–63.9) | 100 (86.7–100) |
| Combination of sample sitesc | ||
| Unilateral nasopharyngeal + throat | 91.7 (82.4–96.6) | 100 (86.7–100) |
| Unilateral nasal midturbinate + throat | 89.0 (79.0–94.8) | 100 (86.7–100) |
| Unilateral nasal midturbinate + saliva | 72.6 (60.7–82.1) | 100 (86.7–100) |
| Throat + saliva | 83.6 (72.7–90.9) | 100 (86.7–100) |
aAll samples (unless otherwise stated) were tested with the A*STAR Fortitude Kit (Accelerate Technologies, Singapore).
bA second polymerase chain reaction assay targeting the N and ORF1ab genes was used for saliva samples.
cFor data for sample site combinations, data from the A*STAR Fortitude Kit were used for saliva.